Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04938583 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer

StatusActive, Not Recruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date changed from estimate of Apr 30, 2024 to Oct 30, 2025 Trial status: Recruiting to Active, Not Recruiting · Completion date: Dec 31, 2025 to Aug 31, 2026 · Site details revised at 6 of 6 sitesv4 Show 3 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Completion date: Dec 31, 2025 to Aug 31, 2026
    • Site details revised at 6 of 6 sites
  2. Primary completion date: Apr 30, 2023 to Apr 30, 2024v3
  3. Primary completion date: Dec 31, 2021 to Apr 30, 2023 Study sites: 3 to 6 · Secondary endpoints: details revised at 2 of 2 entries · Eligibility criteria expanded, about 5 wordsv2 Show 3 more changesShow less
    • Study sites: 3 to 6
    • Secondary endpoints: details revised at 2 of 2 entries
    • Eligibility criteria expanded, about 5 words

    See this version in full on ClinicalTrials.gov ↗

  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a single arm phase 1b/2 evaluation of the combination of oregovomab, and bevacizumab, paclitaxel carboplatin in adult subjects with CA125-associated, advanced recurrent epithelial ovarian, fallopian tube or peritoneal carcinoma (FIGO Stage III/IV) with BRCA-wild type, previously treated with 1 prior lines of therapy, and with platinum free intervals of \>6 months since last platinum-based treatment.
Trial Details
NCT Number NCT04938583
Lead Sponsor CanariaBio Inc.
Collaborators: Korean Cancer Study Group
Conditions Ovarian Cancer by FIGO Stage, Ovarian Cancer Stage III, Ovarian Cancer Stage IV
Enrollment 54 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov